Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
“In some cancers (for example, ovarian), hypoxia-induced HIF-1-mediated apoptosis might represent an important factor in the positive selection of p53-null and BCL2-overexpressing cell”
BackgroundRisau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
“At this penumbral layer, microenvironmental selection forces will favour phenotypes that adapt to harsh environments (through resistance to hypoxia and acid-induced cell toxicity) and successfully compete for scarce resources, such as oxygen and glucos”
BackgroundMatrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Self-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
“The many effects of hypoxia on tumour biology include: selection of genotypes favouring survival under hypoxia–re-oxygenation injury (such as TP53 mutation”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
“Finally, in addition to its effect on response to cytotoxic therapy, it has also been demonstrated that hypoxia in tumours tends to select for a more malignant phenotyp”
BackgroundTumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
“In addition, loss of HIF-1α affected tumour growth by progressive selection of intensely proliferating cells, as occurs in the absence of p53”
BackgroundSelf-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
“Because hypoxia can induce apoptosis in a p53-dependent manner (Graeber et al. 1996), low oxygen conditions can provide a selective advantage for cells carrying mutations in p53, allowing escape from apoptosis.”
BackgroundHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
“This perfusion-lim- CELL METABOLISM 3, 187–197, MARCH 2006 ª2006 ELSEVIER INC. ited hypoxia is a potent microenvironmental stress during tumor evolution (Graeber et al., 1996; Hockel and Vaupel, 2001) and an important variable capable of predicting for poor patient outcome.”
BackgroundHypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R. T., Remotti, H., Stevens, J. L., & Ron, D. (1998) · Genes & Development · doi:10.1101/gad.12.7.982 · Cited by 2,014
“As a consequence perhaps, gain-of-function or loss-of-function mutations in single genes that have an impact on death pathways tend to have rather modest quantitative effects (for examples, see Bissonnette et al. 1992; Lowe et al. 1993; Graeber et al. 1996).”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
“Several models (not mutually exclusive) have been proposed to explain the high frequency of p53 inactivatio”
BackgroundRegulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Self-citationVascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
“HIF-1 has been found to be overexpressed in most human cancers, since active tumor growth is accompanied by hypoxia (Graeber et al., 1996; Elson et al., 2000).”
BackgroundPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
“Hypoxia and acidosis also select for metastatic tumour cells, which are resistant to hypoxia and cytotoxic drug”
BackgroundKaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“Hypoxia-exposed cancer cells are selective for the loss of p53 functions or increased expressions of the p53 negative regulator (MDM2), leading to increased resistance to apoptosis and increased metastasis.(124,125) Other experiments did not find correlation between hypoxia and p53.”
BackgroundHIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
“These hypoxic areas of the tumor form a depot of cells resistant to p53-mediated apoptosis and are thus likely locations of selection for mutations in p53 prior to invasive growth and metastasis (Graeber et al., 1996).”
BackgroundClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
“Drug resistance Hypoxia selects for tumour cells with diminished apoptotic potentia”
BackgroundA Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Mitochondrial control of apoptosis
Kroemer, G., Zamzami, N., & Susin, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80014-x · Cited by 1,471
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
“increased tumor hypoxia and favor the selection of invasive tumor cells, enhancing the risks of metastatic spread [106, 107].”
BackgroundThe impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
“Hypoxia exerts a selective pressure on cells for loss of p53, a key mediator of apoptosis, and upregulates the expression of the multidrug resistance gene ( MDR1 , also known as ABCB1 ), leading to efflux of chemotherapeutic drug”
BackgroundThe complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
“Future studies will be required to understand the role of protein phosphorylation and protein‐protein interaction in p53 stabilization under hypoxic conditions, and how these interactions affect p53’s biological activity in promoting apoptosis ( Graeber et al. 1996; Kim et al. 1997).”
BackgroundSelf-citationHypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia
Carreau, A., Hafny‐Rahbi, B. E., Matejuk, A., Grillon, C., & Kieda, C. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01258.x · Cited by 1,246
“Furthermore, modifications in sensitivity to p53-mediated apoptosis and in DNA mismatch repair make cells resistant to platinum-based chemotherapeutic agents (as carboplatin or cisplatin) [33, 34].”
BackgroundLife and death partners: apoptosis, autophagy and the cross-talk between them
Eisenberg-Lerner, A., Bialik, S., Simon, H.-U., & Kimchi, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.33 · Cited by 1,183
(1996) · PubMed · Cited by 1,188
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
“It has also been reported that exposure to hypoxia can select for cells with loss of p53 function and increased ability to withstand apoptotic stimul”
BackgroundHochachka, P. W., Buck, L. T., Doll, C. J., & Land, S. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9493 · Cited by 1,105
Oncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,230
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00101-6 · Cited by 1,068
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
“Clonal evolution of tumor cells in this hypoxic microenvironment results from selection of subpopulations that not only resist apoptosis (Graeber et al. 1996) but also promote the formation of new blood vessels (for review, see Hanahan and Folkman 1996; Folkman 1997).”
BackgroundLin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
“p53 can promote cell-cycle arrest or apoptosis in response to a variety of cellular stresses, including DNA damage and hypoxia (Kastan 1993; Graeber et al. 1996).”
BackgroundSelf-citationNordsmark, M., Overgaard, M., & Overgaard, J. (1996) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(96)91811-3 · Cited by 942
Regulation of Human Placental Development by Oxygen Tension
Genbacev, O., Zhou, Y., Ludlow, J. W., & Fisher, S. J. (1997) · Science · doi:10.1126/science.277.5332.1669 · Cited by 914
HIF-1 and human disease: one highly involved factor
Semenza, G. L. (2000) · Genes & Development · doi:10.1101/gad.14.16.1983 · Cited by 909
“HIF-1 -mediated stabilization of p53 may also play a role in hypoxia-mediated apoptosis leading to selection for loss of p53 function in tumor cells (Graeber et al. 1996).”
BackgroundHypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Rozpedek, W., Pytel, D., Mucha, B., Leszczynska, H., Diehl, J. A., & Majsterek, I. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160523143937 · Cited by 867
“Tumors have significant interruptions in blood flow [33] and have poorly oxygenated areas spread within the mass [34, 35].”
BackgroundHypoxia-induced neutrophil survival is mediated by HIF-1α–dependent NF-κB activity
Walmsley, S. R., Print, C., Farahi, N., Peyssonnaux, C., Johnson, R. S., Cramer, T., Sobolewski, A., Condliffe, A. M., Cowburn, A. S., Johnson, N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20040624 · Cited by 891
“The induction of these key glycolytic enzymes provides a mechanism for the continued generation of ATP, which is an essential requirement for neutrophil functional responses to inflammatory stimuli (39).”
BackgroundThe Role of Hypoxia-Induced Factors in Tumor Progression
Vaupel, P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-10 · Cited by 827
“It has also been suggested that hypoxia exerts a strong selection pressure on malignant cells [5, 6, 51 , 52].”
BackgroundLoss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
“Thus, apoptosis driven by the tumor microenvironment could potentially select for loss of negative regulators of apoptosis, such as PTEN, as has been shown for other tumor suppressors that regulate apoptosis, such as p53 (Graeber et al. 1996).”
BackgroundSelf-citationEssential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes
Woo, M., Hakem, R., Soengas, M. S., Duncan, G. S., Shahinian, A., Kagi, D., Hakem, A., McCurrach, M., Khoo, W., Kaufman, S. A., et al. (1998) · Genes & Development · doi:10.1101/gad.12.6.806 · Cited by 840
“DNA breaks caused by g-irradiation, the presence of DNA repair intermediates from UV-irradiation, and other stress signals such as hypoxia or drugs have all been shown to increase levels of p53 (Lowe et al. 1993; Lee et al. 1995; Martin et al. 1995; Graeber et al. 1996).”
BackgroundSelf-citationRouschop, K. M. A., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J. W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40027 · Cited by 829
“This was first demonstrated by the selective outgrowth of hypoxia-resistant p53-deficient cells (8).”
Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller‐Klieser, W. (2000) · PubMed · Cited by 850
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis: Figure 1
Greijer, A. E., & van der Wall, E. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015032 · Cited by 784
Hlatky, L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.883 · Cited by 787
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., & Johnson, R. S. (2000) · PubMed · Cited by 888
Acid-Mediated Tumor Invasion: a Multidisciplinary Study
Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4193 · Cited by 771
“This is observed experimentally as tumor cells survive and proliferate in pHe significantly lower than that of normal cells (21, 22, 32), perhaps due to constitutive up-regulation of H transporters or mutations in p53, caspase, or downstream effectors (22).”
BackgroundThe role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
Proteases for Cell Suicide: Functions and Regulation of Caspases
Chang, H. Y., & Yang, X. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.821-846.2000 · Cited by 740
“As cancer cells proliferate, decreased apoptotic sensitivity allows cancer cells to survive the hypoxic environment within tumors; indeed, experimental hypoxia selects for cells that have p53 mutations (69).”
BackgroundChen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/381713a0 · Cited by 728
Sowter, H., Ratcliffe, P. J., Watson, P. H., Greenberg, A. H., & Harris, A. L. (2001) · PubMed · Cited by 828
Role of redox potential and reactive oxygen species in stress signaling
Adler, V., Yin, Z., Tew, K. D., & Ronai, Z. (1999) · Oncogene · doi:10.1038/sj.onc.1203128 · Cited by 697
“Furthermore, an increased tumor cells capacity for undergoing apoptosis in response to ROS was also shown to be p53-dependent (Graeber et al., 1996).”
BackgroundApoptosis, p53, and tumor cell sensitivity to anticancer agents.
Brown, J. M., & Wouters, B. G. (1999) · PubMed · Cited by 771
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3298 · Cited by 684
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
BackgroundInfluentialResistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Metabolic control of cell death
Green, D. R., Galluzzi, L., & Kroemer, G. (2014) · Science · doi:10.1126/science.1250256 · Cited by 647
“Prolonged hypoxia (78, 79) as well as an increased availability of succinate (which occurs, for example, in individuals bearing inactivating loss-of-function mutations in succinate dehydrogenase or fumarate hydratase) (77) promotes a HIF-1–dependent state of resistance to apoptosis.”
BackgroundMolecular landmarks of tumor hypoxia across cancer types
Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678
Pucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Pancreatic tumors show high levels of hypoxia
Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., Bastidas, A. J., & Vierra, M. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00803-8 · Cited by 650
Radiation oncology: a century of achievements
Bernier, J., Hall, E. J., & Giaccia, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1451 · Cited by 628
“Although few argue that activating the apoptotic machinery will increase the ability of tumours to be controlled by radiotherapy, especially when this radiotherapy is fractionated, there has been debate since the 1990s as to the extent of the contribution of apoptosis to the control of human tumours by radiotherapy an…”
BackgroundSelf-citationApaf-1 and Caspase-9 in p53-Dependent Apoptosis and Tumor Inhibition
Soengas, M. S., Alarcón, R. M., Yoshida, H., J., A., Giaccia, Hakem, R., Mak, T. W., & Lowe, S. W. (1999) · Science · doi:10.1126/science.284.5411.156 · Cited by 660
Self-citationMOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
“There is some debate as to whether p53 mediates apoptosis of tumor cells in response to hypoxia (Graeber et al., 1996) or hypoxia-induced lactic acidosis (Schmaltz et al.”
BackgroundInfluentialBrown, J. M. (1999) · PubMed · Cited by 698
Causes and Consequences of Increased Glucose Metabolism of Cancers
Gillies, R. J., Robey, I., & Gatenby, R. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047258 · Cited by 623
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
(2003) · PubMed · Cited by 624
(2000) · PubMed · Cited by 614
(2001) · PubMed · Cited by 605
Oxygenation predicts radiation response and survival in patients with cervix cancer
Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M.-C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., et al. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(98)00044-9 · Cited by 597
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593
Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., & Mueller-Klieser, W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01630-3 · Cited by 586
Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage
Kim, S.-T., Xu, B., & Kastan, M. B. (2002) · Genes & Development · doi:10.1101/gad.970602 · Cited by 583
“1992) and other cellular stresses (Graeber et al. 1996) has had a major impact on models of tumor development involving p53 mutations and on studies evaluating tumor responses to therapy based on the presence or absence of p53 mutations (Vogelstein et al.”
BackgroundXBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., Glimcher, L. H., Denko, N. C., Giaccia, A. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1606 · Cited by 570
“The cellular response to ER stress consists of at least two coordinated pathways: (1) rapid translational arrest mediated by pancreatic ER kinase or PKR-like ER kinase (PERK); and (2) transcriptional activation of unfolded protein response target genes (5, 6).”
BackgroundSelf-citationThe role of p53 in determining sensitivity to radiotherapy
Gudkov, A. V., & Komarova, E. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc992 · Cited by 572
“cgi?l=12043">Bcl2 or lack p53 have similar growth advantages in vivo”
BackgroundThe impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 546
“Mazzone is supported by a European Research Council (ERC) starting grant and a Worldwide Cancer Research grant (13-1031).”
PUMA mediates the apoptotic response to p53 in colorectal cancer cells
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 563
Treatment Resistance of Solid Tumors
Vaupel, P., Thews, O., & Hoeckel, M. (2001) · Medical Oncology · doi:10.1385/mo:18:4:243 · Cited by 558
Rasey, J. S., Koh, W.-J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., & Krohn, K. A. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00325-2 · Cited by 562
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.